Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advanced-generation macrolides: tissue-directed antibiotics.

G W Amsden1

  • 1The Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326-1394, USA. guy.amsden@bassett.org

International Journal of Antimicrobial Agents
|September 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma Pharmacokinetics and Tissue Penetration of Alatrofloxacin in Morbidly Obese Individuals.

Clinical drug investigation·2016
Same author

Pharmacokinetic study of azithromycin with fluconazole and cotrimoxazole (trimethoprim-sulfamethoxazole) in healthy volunteers.

Clinical drug investigation·2013
Same author

Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers.

Clinical drug investigation·2008
Same author

Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?

The Journal of antimicrobial chemotherapy·2004
Same author

Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers.

The Journal of antimicrobial chemotherapy·2002
Same author

Pneumococcal resistance: the treatment challenge.

The Annals of pharmacotherapy·2001
Same journal

Strain-dependent variability in pharmacodynamic interactions for phage-antibiotic combinations in Pseudomonas aeruginosa.

International journal of antimicrobial agents·2026
Same journal

Carbapenem-resistant Enterobacterales across the UK: a nationwide study of carbapenemase testing and novel antimicrobial activity.

International journal of antimicrobial agents·2026
Same journal

Kidney Injury, Dialysis, and Mortality with Vancomycin Plus Piperacillin-Tazobactam or Cefepime.

International journal of antimicrobial agents·2026
Same journal

Ceftaroline pharmacokinetics on ECMO, a pediatric case report.

International journal of antimicrobial agents·2026
Same journal

In reply to the Letter to Editor regarding "Comment on "Development and validation of a predictive model for profiling antibiotic resistance phenotypes of Acinetobacter baumannii strains via clinical MALDI-TOF mass spectra: A multicenter study".

International journal of antimicrobial agents·2026
Same journal

Comment on "Targeting the human protein disulfide isomerase A3 as a broad-spectrum antiviral approach against human respiratory viruses".

International journal of antimicrobial agents·2026
See all related articles

Advanced-generation macrolides like azithromycin offer improved pharmacokinetic profiles, featuring high tissue concentrations and extended half-lives. This enables shorter dosing regimens for respiratory tract infections, enhancing treatment efficacy.

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Erythromycin was the first clinically used macrolide antibiotic.
  • Advanced-generation macrolides include azithromycin, clarithromycin, dirithromycin, and roxithromycin.
  • These newer macrolides exhibit distinct pharmacokinetic properties compared to erythromycin.

Purpose of the Study:

  • To compare the pharmacokinetic and pharmacodynamic properties of advanced-generation macrolides, particularly azithromycin.
  • To highlight the clinical utility of azithromycin's tissue-specific concentrations.
  • To emphasize the need for new models to explain the efficacy of intracellularly concentrated antibiotics.

Main Methods:

  • Review of pharmacokinetic data for azithromycin and other advanced-generation macrolides.

Related Experiment Videos

  • Analysis of antimicrobial spectrum, including Gram-positive, atypical, anaerobic, and Gram-negative pathogens.
  • Discussion of azithromycin's concentration within polymorphonuclear leukocytes and at infection sites.

    • Main Results:

    • Advanced-generation macrolides demonstrate low serum and high tissue concentrations, with azithromycin having an extended tissue elimination half-life.
    • Azithromycin allows for a 3-day once-daily dosing regimen for respiratory tract infections, shorter than other macrolides.
    • These macrolides are concentrated in leukocytes, leading to high intracellular pathogen exposure.
    • Azithromycin and clarithromycin's metabolite show activity against community-acquired Gram-negative organisms like Haemophilus influenzae.

    Conclusions:

    • Azithromycin's unique pharmacokinetic profile, characterized by high and prolonged tissue concentrations, supports its clinical efficacy.
    • Traditional pharmacodynamic models are insufficient for explaining the effectiveness of antibiotics achieving high intracellular concentrations.
    • Future research should focus on tissue pharmacokinetic and pharmacodynamic concepts for azithromycin.